Compare AbbVie Inc (ABBV) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Charter Communications Inc — how do they compare? AbbVie Inc trades at $253.75 (market cap $449.91B), while Charter Communications Inc trades at $133.07 (market cap $16.97B). The key difference: AbbVie Inc is far larger — about 26.5× Charter Communications Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| ABBV | CHTR | |
|---|---|---|
Market Cap | $449.91B | $16.97B |
Sector | Health | Media |
52-Week High | $261.07 | $411.66 |
52-Week Low | $184.85 | $125.54 |
Enterprise Value | $513.38B | $113.28B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Charter Communications (CHTR) trades at $138.02, up 0.6% on the day, with a bearish technical signal but deeply discounted valuation metrics including a P/E of 3.66 and EV/EBITDA of 5.32. Recent news highlights a potential mobile partnership with SpaceX, driving significant pre-market gains, while financials show stable revenue near $54.8B and improving operating cash flow to $16.08B in 2025.
The stock presents a high-risk, high-reward opportunity, with a consensus price target of $214 suggesting 55% upside, but faces headwinds from high debt, competitive pressures, and inconsistent earnings beats. Investor sentiment is mixed, balancing low valuation against operational challenges and leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
